Short answer
Beta Bionics, Inc. (BBNX) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter results for period ended September 30, 2026 announced.
Beta Bionics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026 announced
- Press release contains the company’s financial performance details and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $35.5M, up 30% YoY, driven by PBP sales of $13.6M, up 118%
- Gross margin 57.3%, while operating loss widened to $26.6M and adjusted EBITDA loss to $18.9M
- Cash, equivalents and investments $373.6M; public offering added approximately $161.3M net proceeds
- 2026 revenue guidance raised to approximately $124M-$126M, despite potential fourth-quarter deferrals of up to $8.5M
- FDA clearance for Mint supports planned U.S. launch in Q1 2027, while 3D Intelligence resubmission targets mid-Q4 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Beta Bionics, Inc. 8-K filings
Get the next BBNX 8-K as it lands
Follow BBNX for push alerts, or ask the research agent what this filing means.